Tanios Bekaii-Saab, MD is a Professor of Medicine at the Mayo Clinic College of Medicine and Science. He is the Chair for Hematology and Medical Oncology for the Division of Hematology/Oncology at the Mayo Clinic in Phoenix, Arizona, USA. He is the leader of the Gastrointestinal Cancer for the Enterprise-wide Mayo Clinic Cancer Center Dr. Bekaii-Saab is currently the co-leader of the Hepatobiliary Cancer Sub-Committee of the Alliance for Clinical Trials in Oncology and the Co-Chair for the National Cancer Institute’s Hepatobiliary Task Force.

 

Dr. Bekaii-Saab earned his medical degree from the American University of Beirut in Lebanon and completed a residency in internal medicine at Indiana University Medical Center in Indianapolis, Indiana, USA. He then completed fellowships in clinical pharmacology and experimental therapeutics and hematology/oncology at Tufts University/New England Medical Center in Boston, Massachusetts, USA.

Dr. Bekaii-Saab served as a reviewer for many high impact journals and sits on the editorial board of the prestigious Journal of the National Cancer Institute. Dr. Bekaii-Saab has authored or co-authored more than 500 peer reviewed publications, abstracts, and book chapters, including papers in such journals as New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology, JAMA, Journal of the National Cancer Institute, Annals of Oncology, and Clinical Cancer Research.

Prof. Tanios Bekaii-Saab has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Research Funding (to institution): Agios, Arys, Arcus, Atreca, Boston Biomedical, Bayer, Eisai, Celgene, Lilly, Ipsen, Clovis, Seattle Genetics, Genentech, Novartis, Mirati, Merus, Abgenomics, Incyte, Pfizer, BMS. Consulting (to institution): Servier, Ipsen, Arcus, Pfizer, Seattle Genetics, Bayer, Genentech, Incyte, Eisai, Merus, Merck KGaA and Merck. Consulting (to self): Stemline, AbbVie, Blueprint Medicines , Boehringer Ingelheim, Janssen, Daiichi Sankyo, Natera, TreosBio, Celularity, Caladrius Biosciences, Exact Science, Sobi, Beigene, Kanaph, AstraZeneca, Deciphera, Zai Labs, Exelixis, MJH Life Sciences, Aptitude Health, Illumina, Foundation Medicine and Sanofi. Glaxo SmithKline , Xilio. IDMC/DSMB: The Valley Hospital, Fibrogen, Suzhou Kintor, AstraZeneca, Exelixis, Merck/Eisai, PanCan and 1Globe.  Scientific Advisory Board: Imugene, Immuneering, Xilis, Replimune, Artiva and Sun Biopharma. Royalties: Uptodate. Inventions/Patents: WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene, WO/2019/055687: METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion